Skip to content

Global BioLife

  • Back
PRESS RELEASE

SeD PR Ebola

Singapore eDevelopment Limited (Stock Code 40V)’s biomedical subsidiary confirms the LB2 drug efficacy against Ebola

Author adminPosted on 28/02/201814/03/2018

Post navigation

Previous Previous post: SeD Initial Cancer
  • Back
Global BioLife Proudly powered by WordPress